Obtenga las últimas noticias sobre las acciones de Assembly Biosciences con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de ASMB

Últimas noticias sobre

ASSEMBLY BIOSCIENCES INC

Assembly Biosciences

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences Inc

News

Health Care

Press Releases

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

Biotech

General

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

Earnings

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe

Assembly Biosciences Announces Upcoming Investor Conference Participation

ASMB

Abeona Therapeutics

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cabaletta Bio

Crescent Biopharma

C4 Therapeutics

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Fennec Pharmaceuticals Inc. - Common Stock

Fennec Pharmaceuticals

Foghorn Therapeutics

Genfit

Heron Therapeutics

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Pyxis Oncology

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Tenaya Therapeutics

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Exagen

Zura Bio Limited - Class A Ordinary shares

Comments

Assembly Biosciences Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL